TrialThe Lancet. Global health2020

Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial.

Vijay Patil et al.PubMed ↗Publisher ↗

No numbers read from the abstract.